1-2 of 2
Philip Iversen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth

Michele C. Smith, Mary M. Mader, James A. Cook, Philip Iversen, Rose Ajamie, Everett Perkins, Laura Bloem, Yvonne Y. Yip, David A. Barda, Philip P. Waid, Douglas J. Zeckner, Debra A. Young, Manuel Sanchez-Felix, Gregory P. Donoho, Volker Wacheck
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (10): 2344–2356.
https://doi.org/10.1158/1535-7163.MCT-15-0996
Published: 02 October 2016
View article titled, Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
Open the PDF for Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth in another window
Includes: Supplementary data
Journal Articles

Antisense Inhibition of Survivin Expression as a Cancer Therapeutic

Rosa A. Carrasco, Nancy B. Stamm, Eric Marcusson, George Sandusky, Philip Iversen, Bharvin K.R. Patel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (2): 221–232.
https://doi.org/10.1158/1535-7163.MCT-10-0756
Published: 08 February 2011
View article titled, Antisense Inhibition of Survivin Expression as a Cancer Therapeutic
Open the PDF for Antisense Inhibition of Survivin Expression as a Cancer Therapeutic in another window
Includes: Supplementary data